Kuzuya, T.; Kawabe, N.; Ariga, M.; Ohno, E.; Funasaka, K.; Nagasaka, M.; Nakagawa, Y.; Miyahara, R.; Shibata, T.; Takahara, T.;
et al. Clinical Outcomes of Cabozantinib in Patients Previously Treated with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma—Importance of Good Liver Function and Good Performance Status. Cancers 2023, 15, 2952.
https://doi.org/10.3390/cancers15112952
AMA Style
Kuzuya T, Kawabe N, Ariga M, Ohno E, Funasaka K, Nagasaka M, Nakagawa Y, Miyahara R, Shibata T, Takahara T,
et al. Clinical Outcomes of Cabozantinib in Patients Previously Treated with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma—Importance of Good Liver Function and Good Performance Status. Cancers. 2023; 15(11):2952.
https://doi.org/10.3390/cancers15112952
Chicago/Turabian Style
Kuzuya, Teiji, Naoto Kawabe, Mizuki Ariga, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Yoshihito Nakagawa, Ryoji Miyahara, Tomoyuki Shibata, Takeshi Takahara,
and et al. 2023. "Clinical Outcomes of Cabozantinib in Patients Previously Treated with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma—Importance of Good Liver Function and Good Performance Status" Cancers 15, no. 11: 2952.
https://doi.org/10.3390/cancers15112952
APA Style
Kuzuya, T., Kawabe, N., Ariga, M., Ohno, E., Funasaka, K., Nagasaka, M., Nakagawa, Y., Miyahara, R., Shibata, T., Takahara, T., Kato, Y., & Hirooka, Y.
(2023). Clinical Outcomes of Cabozantinib in Patients Previously Treated with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma—Importance of Good Liver Function and Good Performance Status. Cancers, 15(11), 2952.
https://doi.org/10.3390/cancers15112952
